{"entity":{"id":"genfleet","kind":"company","name":"GenFleet Therapeutics","aka":["劢维医药","Genfleet Therapeutics (Shanghai)","GenFleet Therapeutics"],"tldr":"GenFleet discovered fulzerasib, the first KRAS G12C inhibitor approved in China, and licensed it to Innovent for the Chinese market.","summary":"GenFleet Therapeutics, based in Shanghai and founded in 2017, discovered fulzerasib, the first KRAS G12C inhibitor approved in China, and licensed it to Innovent for the Chinese market. Fulzerasib, also GFH925 and sold as Dupert, was approved in August 2024; the KRAS G12C programme is partnered with Verastem in the United States as VS-7375, formerly GFH375, combination trials with cetuximab are running, and KRAS G12D and pan-RAS inhibitors are in development. OnCo links it to fulzerasib, Innovent Biologics and Verastem Oncology. Whether a Chinese-discovered KRAS inhibitor can compete in the West through a partner against the established G12C drugs is the open question. Fulzerasib has its own page.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.genfleet.com/en/"}],"tags":["china"],"related":[],"cancers":[],"sections":["targeted-therapy"],"technologies":[],"targets":[],"drugs":["fulzerasib","gfh375"],"companies":["innovent","verastem"],"institutions":[],"pathways":[],"terms":[],"trials":["nct06214143","nct05944224","nct06434597","nct05872347","nct05934513","nct06375733","nct07259590","nct06500676"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Shanghai","country":"CN","companyType":"biotech","website":"https://www.genfleet.com/en/","founded":2017,"investors":[],"funding":[]},"route":"/companies/genfleet/","neighbours":{"section":[{"id":"targeted-therapy","kind":"section","name":"Targeted Therapy","route":"/fronts/targeted-therapy/"}],"drug":[{"id":"fulzerasib","kind":"drug","name":"Fulzerasib","route":"/drugs/fulzerasib/"},{"id":"gfh375","kind":"drug","name":"GFH375","route":"/drugs/gfh375/"}],"company":[{"id":"innovent","kind":"company","name":"Innovent Biologics","route":"/companies/innovent/"},{"id":"verastem","kind":"company","name":"Verastem Oncology","route":"/companies/verastem/"}],"trial":[{"id":"nct06434597","kind":"trial","name":"A Clinical Study of SPH5030 Tablets in the Treatment of Her2-positive/Mutated Biliary Tract OR Colorectal Cancer Patients.","route":"/trials/nct06434597/"},{"id":"nct06214143","kind":"trial","name":"A Clinical Study of T3011 in Combination With PD-1/PD-L1 Inhibitors in Subjects With Advanced Solid Tumors","route":"/trials/nct06214143/"},{"id":"nct07784374","kind":"trial","name":"A Phase II Study of GFH375 Combined With GFS202A or GFH276 Versus GFH375 Monotherapy in Patients With Previously Treated Locally Advanced Unresectable or Metast","route":"/trials/nct07784374/"},{"id":"nct07198321","kind":"trial","name":"A Single-Arm, Open-Label, Multicenter Phase I/II Clinical Study of GFH276 in Patients With RAS-Mutant Advanced Solid Tumors","route":"/trials/nct07198321/"},{"id":"nct06375733","kind":"trial","name":"A Study of GFH009 in Combination With Zanubrutinib in Subjects With Relapsed or Refractory DLBCL","route":"/trials/nct06375733/"},{"id":"nct05934513","kind":"trial","name":"A Study of GFH009 Monotherapy in Patients with Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)","route":"/trials/nct05934513/"},{"id":"nct07678593","kind":"trial","name":"A Study of GFH276 Combined With Cetuximab or Chemotherapy in Participants With Solid Tumors and Pancreatic Ductal Adenocarcinoma (PDAC) Harboring RAS Mutation","route":"/trials/nct07678593/"},{"id":"nct07259590","kind":"trial","name":"A Study of GFH375 Combined With Cetuximab or Chemotherapy in Participants With Solid Tumors Harboring KRAS G12D Mutation","route":"/trials/nct07259590/"},{"id":"nct06500676","kind":"trial","name":"A Study of GFH375 in Patients With Advanced Solid Tumors With KRAS G12D Mutations","route":"/trials/nct06500676/"},{"id":"nct05944224","kind":"trial","name":"A Study to Efficacy and Safety of SPH4336 Monotherapy or in Combination With Cadonilimab in Patients With Advanced Solid Tumors.","route":"/trials/nct05944224/"},{"id":"nct07668752","kind":"trial","name":"A Study to Evaluate GFH375 Versus Docetaxel in Participants With Non-Small Cell Lung Cancer With KRAS G12D Mutation","route":"/trials/nct07668752/"},{"id":"nct05872347","kind":"trial","name":"Efficacy and Safety of SPH4336 in Combination With Endocrine Therapy in Breast Cancer Patients With Brain Metastases.","route":"/trials/nct05872347/"},{"id":"nct07554859","kind":"trial","name":"GFH375 Monotherapy and Combination Therapy as First-Line Treatment for Advanced KRAS G12D-Mutant Non-Small Cell Lung Cancer","route":"/trials/nct07554859/"},{"id":"nct07262567","kind":"trial","name":"Phase III Study to Compare GFH375 and Chemotherapy in Patients With KRAS G12D-Mutant Metastatic Pancreatic Cancer","route":"/trials/nct07262567/"}]}}